MedTrace Logo

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

NCT00603811 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-09-23

No results posted yet for this study

Summary

This study will evaluate the safety and immunogenicity of VAX102 \[Flagellin.HuM2e\], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.

Conditions

  • Influenza Infection

Interventions

BIOLOGICAL

VAX102 [Flagellin.HuM2e]

dose ranging, 2 i.m. doses given 28 days apart

BIOLOGICAL

Placebo

Placebo

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • VaxInnate Corporation

    lead INDUSTRY

Principal Investigators

  • Christine Turley, MD · UTMB

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00603811 on ClinicalTrials.gov